← Back to Search

DBV712 for Peanut Allergy (EPOPEX Trial)

Phase 3

Waitlist Available

Research Sponsored by DBV Technologies

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 36 months

Awards & highlights

EPOPEX Trial Summary

This trial is for subjects who have already completed the EPITOPE study. It is an open-label follow-up, which means that both the subjects and the researchers know which treatment the subjects are receiving.

Who is the study for?

This trial is for young children who have completed the EPITOPE study and are dealing with peanut allergies. It's not open to those who've developed severe, unstable asthma or have widespread skin conditions like active eczema that would prevent applying Viaskin patches on clear skin areas.Check my eligibility

What is being tested?

The trial is testing the long-term efficacy and safety of a treatment called DBV712 at a dose of 250 mcg. This is an open-label follow-up study, meaning everyone knows they're getting the treatment and it's a continuation from an earlier phase.See study design

What are the potential side effects?

While specific side effects aren't listed here, treatments like DBV712 could potentially cause skin reactions where the patch is applied or allergic responses due to its nature as a therapy for peanut allergy.

EPOPEX Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of subjects reaching an ED ≥1000 mg

Secondary outcome measures

Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)

EPOPEX Trial Design

1Treatment groups

Experimental Treatment

Group I: DBV712 250mcgExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

DBV TechnologiesLead Sponsor

16 Previous Clinical Trials

3,192 Total Patients Enrolled

Media Library

DBV712 250 mcg Clinical Trial Eligibility Overview. Trial Name: NCT03859700 — Phase 3

Peanut Allergy Research Study Groups: DBV712 250mcg

Peanut Allergy Clinical Trial 2023: DBV712 250 mcg Highlights & Side Effects. Trial Name: NCT03859700 — Phase 3

DBV712 250 mcg 2023 Treatment Timeline for Medical Study. Trial Name: NCT03859700 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research allow people who are over 45 years old to participate?

"According to the eligibility requirements for this particular clinical trial, toddlers aged two and four years old are able to enroll."

Answered by AI

In how many different locations is this trial being run today?

"If you enroll in this study, it is important to choose the site that is closest to your location from the 8 sites recruiting patients. The locations are situated in Boston, Baltimore, Philadelphia and 8 other cities."

Answered by AI

Is this research project still looking for test subjects?

"Unfortunately, this specific trial is not currently recruiting patients. Although the last update was on March 3rd, 2022, the study has not been actively recruiting since December 6th 2018. However, there are 30 other studies that potential candidates could look into."

Answered by AI